Transcatheter Cardiovascular Therapeutics (TCT) conference has announced a list of three late-breaking clinical trial sessions to be presented in March.

THT 24 will occur from March 4th to March 6th at the Westin Boston Seaport in Boston, Massachusetts. Access the full programme here. 

Featured Late-Breaking Clinical Science Abstracts I

Tuesday, March 5th, 14:00 – 15:17 Eastern Standard Time

• One Year Outcomes of Left Atrial to Coronary Sinus Shunting for Treatment of Symptomatic Heart Failure; The ALT FLOW Early Feasibility Study One Year Results – Dr Firas Zahr
• The Pivotal ALIVE Trial of the Revivent TC Transcatheter Ventricular Enhancement System in Heart Failure Patients with Prior Anterior Myocardial Infarction – Dr Jerry D Estep
• Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results – Dr Sanjiv J. Shah
• Initial Experience with Transcatheter Myotomy (SESAME) to Treat Hypertrophic Cardiomyopathy and Left Ventricular Outflow Obstruction – Dr Adam B. Greenbaum
• Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study – Dr Palak Shah
• Cardiac Pulmonary Nerve Stimulation Improves Outcomes of Patients with Acute Decompensated Heart Failure: Results of the STOP-ADHF Pilot Study – Dr Sitaramesh Emani
• An International Multicenter Report on Long-Term Outcomes after LVAD Explantation - The VAD Wean Registry – Dr Snehal R. Patel

Featured Late-Breaking Clinical Science Abstracts II

Tuesday, March 5th, 16:30 – 17:47 Eastern Standard Time

• RECOVER-HF Pilot Study: Synchronized Diaphragmatic Stimulation for HFrEF Therapy – Dr Marat Fudim
• Relationship of Patient Adherence to the Performance of a Remote Speech Analysis System to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients – Dr William T. Abraham
• A Nationwide Study of a Remote Patient Monitoring and Intervention Program: The Impact on Heart Failure Clinical Outcomes and Healthcare Cost – Dr David Ian Feldman
• Derivation and Validation of a Multicenter Model to Identify Candidates for Advanced HF Therapies with High Potential to Achieve post-LVAD Reverse Cardiac Remodeling – Dr Stavros G. Drakos
• Short-term Atrial Shunt Device-Induced Changes in Cardiac Structure/Function and Risk of Subsequent Heart Failure Events: Findings from the REDUCE-LAP HF II Randomized Clinical Trial – Dr David M Kaye
• Remote Management of Sitting Pulmonary Artery Pressures Tested Against a Performance Goal of Reduced HF Hospitalizations and All-cause Mortality in a Prospective Multi-Center Open Label PROACTIVE-HF Trial in NYHA Class III Heart Failure – Dr Liviu Klein

Featured Late-Breaking Clinical Science Abstracts III

Wednesday, March 6th, 08:00 – 09:15 Eastern Standard Time

• A Novel Cardiac Scale and Algorithm for Detecting Worsening Congestion Preceding Heart Failure Events (HFEs): A Preliminary Analysis of the SCALE-HF 1 Study – Dr Marat Fudim
• Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance – Dr Jefferey Testani
• Aquapheresis for Management of Decompensated Heart Failure: A Re-appraisal of AVOID-HF – Dr Sean P Pinney
• AI-Assisted Identification of Super responders for Ultrafiltration Can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial – Dr Deya Alkhatib
• Multicenter Development and Validation of a Supervised Machine Learning Risk Model to Predict Right Ventricular Failure Following Mechanical Circulatory Support: The STOP-RVF Score – Dr Stavros G. Drakos
• Introduction Of Guideline Directed Medical Therapy And Native Heart Recovery In Patients Supported By Impella 5.5 – Dr Kanika P. Mody
• Impact Of Rapid Up-Titration of Guideline-Directed Medical Therapies On Quality of Life: Insights From The STRONG-HF Trial – Dr Kamile Cerlinskaite-Bajore